These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21810730)

  • 21. The influence of age and extensive intraductal component histology upon breast lumpectomy margin assessment as a predictor of residual tumor.
    Wazer DE; Schmidt-Ullrich RK; Ruthazer R; DiPetrillo T; Boyle T; Kanski J; Safaii H
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):885-91. PubMed ID: 10571194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy.
    Laird J; Lok B; Siu C; Cahlon O; Khan AJ; McCormick B; Powell SN; Cody H; Wen HY; Ho A; Braunstein LZ
    Ann Surg Oncol; 2018 Jan; 25(1):154-163. PubMed ID: 29094250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selecting patients for breast-conserving therapy: the importance of lobular histology.
    Morrow M; Keeney K; Scholtens D; Wei J; Steel J; Khan SA
    Cancer; 2006 Jun; 106(12):2563-8. PubMed ID: 16683225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of positive margins after initial lumpectomy in elderly women with breast cancer.
    Angarita FA; Acuna SA; McCready DR; Escallon J
    Eur J Surg Oncol; 2018 Jul; 44(7):1048-1053. PubMed ID: 29525464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons.
    Leonardi MC; Maisonneuve P; Mastropasqua MG; Cattani F; Fanetti G; Morra A; Lazzari R; Bazzani F; Caputo M; Rotmensz N; Gerardi MA; Ricotti R; Enrica Galimberti V; Veronesi P; Dicuonzo S; Viale G; Jereczek-Fossa BA; Orecchia R
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):173-181. PubMed ID: 28816144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort Analysis.
    De Lorenzi F; Loschi P; Bagnardi V; Rotmensz N; Hubner G; Mazzarol G; Orecchia R; Galimberti V; Veronesi P; Colleoni MA; Toesca A; Peradze N; Mario R
    Ann Surg Oncol; 2016 Jun; 23(6):1852-9. PubMed ID: 26842491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncological and aesthetic considerations of conservational surgery for multifocal/multicentric breast cancer.
    Patani N; Carpenter R
    Breast J; 2010; 16(3):222-32. PubMed ID: 20565467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
    Moran MS; Yang Q; Haffty BG
    Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
    Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
    Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient selection for breast conservation therapy with magnification mammography.
    Morrow M; Schmidt R; Hassett C
    Surgery; 1995 Oct; 118(4):621-6. PubMed ID: 7570314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients.
    Wolters R; Wöckel A; Janni W; Novopashenny I; Ebner F; Kreienberg R; Wischnewsky M; Schwentner L;
    Breast Cancer Res Treat; 2013 Dec; 142(3):579-90. PubMed ID: 24258258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study.
    Agresti R; Sandri M; Gennaro M; Bianchi G; Maugeri I; Rampa M; Capri G; Carcangiu ML; Trecate G; Riggio E; Lozza L; de Braud F
    Clin Breast Cancer; 2017 Jun; 17(3):219-231. PubMed ID: 28087389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation.
    Ono Y; Yoshimura M; Hirata K; Yamauchi C; Toi M; Suzuki E; Takada M; Hiraoka M; Mizowaki T
    Radiat Oncol; 2019 Jul; 14(1):121. PubMed ID: 31291997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
    Mamtani A; Patil S; Stempel MM; Morrow M
    Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm.
    Hamilton SN; Nichol A; Wai E; Gondara L; Velásquez García HA; Speers C; Diocee R; Truong P
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):381-388. PubMed ID: 30253237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with invasive lobular breast cancer are less likely to undergo breast-conserving surgery: a population based study in the Netherlands.
    Truin W; Roumen RM; Siesling S; van der Heiden-van der Loo M; Duijm LE; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2015 May; 22(5):1471-8. PubMed ID: 25323475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
    Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
    Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility of breast-conserving therapy for younger women with breast cancer.
    Guenther JM; Kirgan DM; Giuliano AE
    Arch Surg; 1996 Jun; 131(6):632-6. PubMed ID: 8645070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.